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Abstract: Adiponectin is an adipocytokine released by the adipose tissue and has multiple roles in the immune system and in 
the metabolic syndromes such as cardiovascular disease, Type 2 diabetes, obesity and also in the neurodegenerative disorders 
including Alzheimer’s disease. Adiponectin regulates the sensitivity of insulin, fatty acid catabolism, glucose homeostasis and 
anti-inflammatory system through various mechanisms. Previous studies demonstrated that adiponectin modulates memory 
and cognitive impairment and contributes to the deregulated glucose metabolism and mitochondrial dysfunction observed in 
Alzheimer’s disease. Here, we aim to summarize recent studies that suggest the potential correlation between adiponectin and 
Alzheimer’s disease.
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Adiponectin was shown to be present in the cerebrospinal 
fluid of rodents [14, 15] and human [16-19]. In addition, 
adiponectin modulates the sensitivity of insulin in brain [20-
22]. Also, adiponectin has a cardinal role in immune system 
in the CNS. Adiponectin decreases the expression of pro- 
inflammatory cytokines [23] and increases the expression of 
anti-inflammatory molecules [24]. To sum up, adiponectin 
has important functions as a regulator of glucose homeostasis 
and insulin mechanism and immune system. Therefore, 
adiponectin suggested as a potential target to cure CNS dise-
ases.
The Effect of Adiponectin on Brain Insulin 
Sys tem
Insulin plays multiple roles for neuronal function and 
survival. In Alzheimer’s disease brain, level of insulin and 
insulin like growth factor-1 (IGF-1) decreases definitely 
compared to normal brain [25, 26]. Both the expression and 
function of insulin and IGF-1 deteriorate with progression of 
Alzheimer’s disease [27]. Adiponectin-mediated activation 
of AMP-activated protein kinase, the p38 mitogen-acti-
Introduction 
Adiponectin is a protein hormone and an adipocytokine 
released by the adipose tissue. Adiponectin has an N-terminal 
collagen-like domain and a C-terminal complement fac-
tor C1q-like globular domain and circulates as trimers, 
hexamers, and a high molecular weight form. Adiponectin 
acts by binding to its receptors, adiponectin receptor type 1 
and type 2. Adiponectin receptors are expressed in skeletal 
muscle, liver, hypothalamus and vascular endothelial cells 
of brain [1-3]. Adiponectin has important roles in the 
metabolic syndromes such as obesity, cardiovascular disease, 
type 2 diabetes and also neurodegenerative disorders [4-
11]. In the central nervous system (CNS), previous studies 
suggest the neuroprotective effects of adiponectin [12, 13]. 
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vated protein kinase and Rab5 leads to increased glucose 
transporter 4 membrane translocation [28, 29]. Adiponectin 
modulates the sensitivity of insulin, glucose metabolism 
[20-22]. In rodents, the deletion of adiponectin gene leads 
to insulin resistance [30, 31]. In humans, a reduced serum 
concentration of adiponectin incurs obesity, insulin resistance 
and type 2 diabetes [32-34]. Impaired proximal signaling of 
insulin receptor also mediates insulin resistance. Decreased 
insulin receptor substrate (IRS) protein levels contribute 
insulin resistance in rodents and humans [35]. The IRS 
protein levels decrease in streptozotocin induced dementia 
rat model which have used to study Alzheimer’s disease as 
animal model compared with sham group (normal control 
group) in the hippocampus (Fig. 1A) and in the cortex (Fig. 
1B). In Alzheimer’s disease, insulin system dysfunction incurs 
severe pathology such as cognitive decline suggesting that 
adiponectin could be an important target for Alzheimer’s 
disease.
Fig. 1. The phospholylation of insu lin 
receptor substrate (IRS)-1 in strep-
tozotocin (STZ) induced dementia rat 
model. To confirm the dysfunction of 
brain insulin system in STZ—induced 
dementia rat model known as common 
animal model to study Alzheimer’s 
disease in vivo, we conducted immu-
nohistochemistry using phospho IRS-
1 antibody. (A) In the hippocampus, 
phospholylation of IRS-1 decreased 
in the STZ induced dementia group 
compared with sham (control group). (B) 
In the cortex, phospholylation of IRS-1 
decreased in the STZ induced dementia 
group compared with sham (control 
group). Green color, phospho IRS-1; red 
color, propidium iodide (PI).
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The Role of Adiponectin on Neuroinflam­
mation
Adiponectin has a cardinal role in immune system in 
CNS. Adiponectin is the most abundant anti-inflammatory 
adipokine and decreases the expression of pro-inflammatory 
cytokines such as tumor necrosis factor-α (TNF-α) [23] and 
increases the expression of anti-inflammatory molecules 
such as interleukin (IL)-10, IL-1 receptor antagonist [24] 
and decreases the activation of the pro-inflammatory signal 
pathway such as nuclear factor-κB pathway [21, 23]. In the 
brain endothelial cell, adiponectin reduces secretion of IL-6 as 
a pro-inflammatory cytokine [6]. As pro-inflammatory factors 
such as TNF-α, IL-6, reactive oxygen species suppress the 
expression of adiponectin in adipocytes, adiponectin levels 
are decreased in obese rodents and humans [36]. In addition, 
adiponectin modulates T cells activation. Adiponectin 
receptors are upregulated on the surface of human T cells 
after antigen stimulation and mediate apoptosis of antigen 
specific T cells resulting in the suppression of antigen specific 
T cells expansion [37]. Also, adiponectin modulates the 
inflam matory function of natural killer cells [38]. Visceral 
adipose tissue is positively associated with risk of insulin 
resi stance and shows higher monocytes infiltration and IL-6 
production than subcutaneous adipose tissue [39, 40]. TNF-α 
also induces serine phosphorylation of IRS1 to modulate 
the downstream effectors of the insulin receptor resulting in 
insulin resistance [41]. Th17 CD4+ T cells are not involved in 
the inflammation of obese mice [42]. Cytotoxic CD8+ T cells 
are significantly increased in adipose tissues of obese mice, 
and depletion of CD8+ T cells reverses inflammation and 
insulin resistance suggesting that obesity-induced infiltration 
of CD8+ T cells deteriorate systemic insulin sensitivity [43]. 
Various immune responses relate with brain insulin resistance 
and adiponectin involves the relationship between immune 
responses and insulin resistance. Collectively, adiponectin 
has multiple roles in immune system and affects brain insulin 
system. Hence, adiponectin may be a promising tar get for 
curing Alzheimer’s disease which associates with inflam-
mation and insulin resistance.
The Potential of Adiponectin to Target Alzhei­
mer’s Disease 
Adiponectin modulates brain metabolism and sensitivity of 
insulin [1, 44] regulating memory and cognitive dysfunction 
[45] and it also regulates severe inflammaion observed in 
mild cognitive impairment and Alzheimer’s disease [46-
48]. In particular, adiponectin contributes to the deregulated 
glucose metabolism and mitochondrial dysfunction observed 
in Alzheimer’s disease [49, 50]. Specifically, adiponectin 
increase in blood insulin, not glucose level in Alzheimer’s 
disease [51]. Insulin dysregulation contribute to Alzheimer’s 
disease pathologies by several mechanisms from reduced 
brain gulcose utilization to neurofibrillary tangle formation 
and increased amyloid β aggregation by insulin degrading 
enzyme inhibition [35-38, 52, 53]. Insulin affects neuronal 
cognition and memory through several levels by regulating 
ion channels, neurotransmitter receptors and synaptic trans-
mission in Alzheimer’s disease brain [39, 40]. Amyloid β 
accumulation induces the oxidative stress and mitochondrial 
dysfunction, and these dysfunctions induces Alzheimer’s 
disease pathogenesis [54-56]. Adiponectin is protective 
against amyloid β neurotoxicity in Alzheimer’s disease [57]. 
Adiponectin modulates amyloid β in Alzheimer’s disease and 
so improves cognition [58]. Previous studies demonstrate that 
the insulin sensitizing action of adiponectin may be another 
mechanism of neuroprotection in Alzheimer’s disease [59, 
60]. In conclusion, adiponectin has a important role in brain 
insulin dysfunction and amyloid β neurotoxicity and immune 
system through a variety of machanisms. Thus, adiponectin is 
a potential target to treat Alzheimer’s disease.
Table 1. Adiponectin related diseases and pathologies
Organ/Tissue Related disease Related pathology Reference
Liver/Pancreas Diabetes Insulin resistance/glucose metabolism dysfunction [4, 7, 9, 15, 20-22, 25, 26, 28-36]
Heart Cardiovascular disease Hypertension/hyperlipidemia/atherosclerosis [20, 21, 23]
Nervous system Alzheimer’s disease Mild cognitive impairment/brain insulin system dysfunction/ 
Aβ accumulation/immune dysfunction
[6, 10, 11, 19-27, 47, 48, 50, 52-54]
Adipose tissue Obesity Fatty acid catabolisdysfunction/inflammation/ 
whole-body energy homeostasis/adiposity
[4, 9, 14, 21, 29, 31, 32, 41, 42]
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Future Perspective
Adiponectin associates with various disease inclu-
ding diabetes, obesity, cardiovascular disease and neuro-
degenerative diseases. Adiponectin plays multiple roles for 
enhancing related pathologies such as insulin resistance, 
hypertention, hyperlipidemia, inflammation, cognitive 
impairment, atherosclerosis (Table 1). Specifically, adipo-
nectin regulates the sensitivity of insulin and modulates 
the immune system and enhances memory and cognitive 
impairment known as common pathologies of Alzheimer’s 
disease. Thus, adiponectin may be a promising therapeutic 
target to alleviate Alzheimer’s disease pathologies such as 
apoptosis and cognitive decline and dysfunctional brain 
insulin system.
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